Rivia Secures €3 Million Seed Funding to Transform Clinical Trials
June 12, 2024, 9:36 pm
Rivia, a Zurich-based startup at the forefront of AI-driven analytics and clinical trial data infrastructure for biotechs, has successfully raised a substantial €3 million in seed funding. This funding round, spearheaded by Speedinvest, marks a significant milestone for Rivia as it aims to address critical inefficiencies in the current clinical trial process.
The infusion of capital will enable Rivia to expand its team across engineering and client services, as well as advance its product development efforts. By fully harnessing the potential of integrated trial data, Rivia seeks to solidify its position as the go-to unified data platform for biopharma clinical trials.
In an industry where only 13% of therapies that enter clinical trials ultimately make it to market, the need for innovation and efficiency is more pressing than ever. Rivia's mission is clear: to revolutionize the lifecycle of clinical trials and empower biotechs to achieve greater success in developing new therapies through cutting-edge technology.
Founded by seasoned biopharma experts who intimately understand the industry's pain points, Rivia is dedicated to creating user-friendly software tailored to the specific needs of biotech firms. By tackling issues such as fragmented data and outdated visualization tools, Rivia is paving the way for a new era in clinical trial management.
Erik Scalfaro, CEO and co-founder of Rivia, expressed his excitement about the company's trajectory, stating, "Our technology transcends data integration and changes how biotechs evaluate their therapies throughout their development lifecycle. We are introducing AI-powered analytics and AI-enabled workflows to enhance data interactions, ultimately equipping biotechs with the tools they need to develop transformative, life-saving therapies."
The significance of Rivia's work cannot be overstated, particularly in light of the industry's shift towards innovative drug treatments such as mRNA vaccines, gene-editing therapies, and AI-discovered drugs. These groundbreaking treatments underscore the urgent need to move away from traditional, slow clinical trial practices towards a more agile, tech-centric approach that can navigate the uncertainties associated with cutting-edge therapies.
Andrea Zitna, Partner at Speedinvest, expressed enthusiasm about the partnership with Rivia, highlighting the company's potential to become the gold standard in the industry. Similarly, Marta G. Zanchi, Founder & Managing Partner at Nina Capital, commended Rivia for its unique approach to centralizing and visualizing clinical trial data in real-time, emphasizing the value it brings to biotechs globally.
With its innovative technology and unwavering commitment to transforming the clinical trial landscape, Rivia is poised to make a lasting impact on the biopharma industry. As the company continues to grow and evolve, it is clear that Rivia's dedication to efficiency, innovation, and excellence will drive positive change in the realm of clinical trials.
The infusion of capital will enable Rivia to expand its team across engineering and client services, as well as advance its product development efforts. By fully harnessing the potential of integrated trial data, Rivia seeks to solidify its position as the go-to unified data platform for biopharma clinical trials.
In an industry where only 13% of therapies that enter clinical trials ultimately make it to market, the need for innovation and efficiency is more pressing than ever. Rivia's mission is clear: to revolutionize the lifecycle of clinical trials and empower biotechs to achieve greater success in developing new therapies through cutting-edge technology.
Founded by seasoned biopharma experts who intimately understand the industry's pain points, Rivia is dedicated to creating user-friendly software tailored to the specific needs of biotech firms. By tackling issues such as fragmented data and outdated visualization tools, Rivia is paving the way for a new era in clinical trial management.
Erik Scalfaro, CEO and co-founder of Rivia, expressed his excitement about the company's trajectory, stating, "Our technology transcends data integration and changes how biotechs evaluate their therapies throughout their development lifecycle. We are introducing AI-powered analytics and AI-enabled workflows to enhance data interactions, ultimately equipping biotechs with the tools they need to develop transformative, life-saving therapies."
The significance of Rivia's work cannot be overstated, particularly in light of the industry's shift towards innovative drug treatments such as mRNA vaccines, gene-editing therapies, and AI-discovered drugs. These groundbreaking treatments underscore the urgent need to move away from traditional, slow clinical trial practices towards a more agile, tech-centric approach that can navigate the uncertainties associated with cutting-edge therapies.
Andrea Zitna, Partner at Speedinvest, expressed enthusiasm about the partnership with Rivia, highlighting the company's potential to become the gold standard in the industry. Similarly, Marta G. Zanchi, Founder & Managing Partner at Nina Capital, commended Rivia for its unique approach to centralizing and visualizing clinical trial data in real-time, emphasizing the value it brings to biotechs globally.
With its innovative technology and unwavering commitment to transforming the clinical trial landscape, Rivia is poised to make a lasting impact on the biopharma industry. As the company continues to grow and evolve, it is clear that Rivia's dedication to efficiency, innovation, and excellence will drive positive change in the realm of clinical trials.